Institutional Owners May Take Dramatic Actions as Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Recent 17% Drop Adds to One-year Losses
Institutional Owners May Take Dramatic Actions as Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Recent 17% Drop Adds to One-year Losses
Key Insights
主要见解
- Significantly high institutional ownership implies Tenaya Therapeutics' stock price is sensitive to their trading actions
- 52% of the business is held by the top 9 shareholders
- Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
- 强大的机构持股意味着Tenaya Therapeutics的股价对他们的交易行动非常敏感。
- 前9大股东持有业务的52%。
- 分析师预测以及所有者数据可以给我们提供有关业务前景的强烈想法。
If you want to know who really controls Tenaya Therapeutics, Inc. (NASDAQ:TNYA), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 44% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道谁真正控制了Tenaya Therapeutics,Inc.(纳斯达克股票代码:TNYA),那么你需要看看它的股权登记簿的构成。 占有44%所有权的机构是拥有最大股份的群体。也就是说,如果股票上涨,该群体将最受益(或者如果出现经济下滑将面临最大风险)。
And so it follows that institutional investors was the group most impacted after the company's market cap fell to US$248m last week after a 17% drop in the share price. Needless to say, the recent loss which further adds to the one-year loss to shareholders of 49% might not go down well especially with this category of shareholders. Institutions or "liquidity providers" control large sums of money and therefore, these types of investors usually have a lot of influence over stock price movements. As a result, if the decline continues, institutional investors may be pressured to sell Tenaya Therapeutics which might hurt individual investors.
因此,当公司市值上周下跌17%的股价跌至2.48亿美元后,机构投资者成为受影响最大的群体。不用说,最近的损失进一步将股东一年的损失增加了49%,特别是对于这类股东而言,这可能不会很好。机构或“流动性提供者”控制着大量资金,因此这些类型的投资者通常对股票价格的波动有很大影响力。结果,如果下跌持续下去,机构投资者可能会受到压力,被迫出售Tenaya Therapeutics的股权,这可能会伤害个人投资者。
Let's take a closer look to see what the different types of shareholders can tell us about Tenaya Therapeutics.
让我们更仔细地看看不同类型的股东可以告诉我们有关Tenaya Therapeutics的信息。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240620/0-36159d8a6f0281ab6598a8dfe77395d1-0-86ea8fff4c7197ce8e66b2b6eb4c61a8.png/big)
What Does The Institutional Ownership Tell Us About Tenaya Therapeutics?
机构投资的持股比例告诉我们关于Tenaya Therapeutics的信息
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构通常在向自己的投资者报告时会针对一个基准进行衡量,因此一旦某只股票被纳入主要指数,他们通常会更加热衷于该股票。我们预计大多数公司都会有一些机构在登记簿上,尤其是那些正在增长的公司。
We can see that Tenaya Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Tenaya Therapeutics' earnings history below. Of course, the future is what really matters.
我们可以看到Tenaya Therapeutics确实有机构投资者;他们持有公司的很大一部分股票。这说明在专业投资者中存在一些可靠性。 但我们不能仅仅依靠这一事实,因为机构有时会像其他人一样犯下投资失败。如果多个机构同时改变对一支股票的看法,那么你可能会看到股价会迅速下跌。因此,值得看看下面的Tenaya Therapeutics盈利历史。当然,未来才是真正重要的。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240620/0-36159d8a6f0281ab6598a8dfe77395d1-1-59e326a9d6385fbd9560e91f5c891874.png/big)
Tenaya Therapeutics is not owned by hedge funds. The Column Group, LLC is currently the largest shareholder, with 12% of shares outstanding. In comparison, the second and third largest shareholders hold about 8.6% and 7.3% of the stock.
Tenaya Therapeutics不是由对冲基金持有。 目前,具有12%流通股的是The Column Group,LLC是最大的股东。相比之下,第二大和第三大股东持有大约8.6%和7.3%的股份。
We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
我们还观察到,前9大股东持有超过股份注册的一半,还有一些小股东平衡大股东的利益。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
尽管研究公司的机构持股可以增加您的研究价值,但研究分析师的建议也是一个好习惯,以更深入地了解股票的预期表现。有相当数量的分析师关注该股,因此了解他们对未来的总体观点可能很有用。
Insider Ownership Of Tenaya Therapeutics
Tenaya Therapeutics的内部股东
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
内部人员的定义在不同国家之间可能略有不同,但董事会成员始终计数。公司管理层回答董事会,在此应代表股东利益。值得注意的是,有时高级管理人员也在董事会上。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。
Shareholders would probably be interested to learn that insiders own shares in Tenaya Therapeutics, Inc.. As individuals, the insiders collectively own US$2.8m worth of the US$248m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.
股东可能会想知道内部人员是否拥有Tenaya Therapeutics股份。作为个人,内部人员共拥有价值280万美元的这家市值为2.48亿美元的公司的股份。看到内部人员进行了一些投资是好的,但看看他们是否一直在购买股票可能更值得。
General Public Ownership
一般大众所有权
The general public-- including retail investors -- own 27% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
一般公众,包括普通投资者,在公司拥有27%的股份,因此不能轻易被忽视。虽然这种所有权的规模可能不足以在他们的利益方面左右政策决策,但他们仍然可以对公司政策产生集体影响。
Private Equity Ownership
股权投资公司持有8.8%的股份,有能力参与塑造以价值创造为重点的公司策略。一些投资者可能会因此而受到鼓舞,因为股权投资公司有时可以鼓励市场看到公司的价值,从而采取有益的策略。另外,那些持有者可能在将其上市后退出投资。
Private equity firms hold a 28% stake in Tenaya Therapeutics. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
私募股权公司持有Tenaya Therapeutics的28%股权。这表明它们在重要政策决策方面具有影响力。一些投资者可能会因此感到鼓舞,因为私募股权投资公司有时能够鼓励制定有助于市场看到公司价值的战略。另外,这些持股人可能将其投资承销后退出。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Tenaya Therapeutics better, we need to consider many other factors. For instance, we've identified 3 warning signs for Tenaya Therapeutics (1 is potentially serious) that you should be aware of.
考虑到公司股权结构是不错的,但要了解Tenaya Therapeutics,还需要考虑许多其他因素。例如,我们为Tenaya Therapeutics确定了3个警告信号(其中1个可能很重要)。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一样,可能希望考虑这家公司是否会增长或缩小。幸运的是,您可以查看此免费报告,显示分析师对其未来的预测。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。